EcoDrugPlus

Cysteinyl Leukotriene Receptor 1

Ensembl ID : ENSACIG00000013356
Gene Symbol: CYSLTR1
1 Cross references
180 Possible Orthologues:

Cytidine Deaminase B

Ensembl ID : ENSACIG00000014687
Gene Symbol: CDAB
1 Cross references
199 Possible Orthologues:

Cytochrome P450 Family 19 Subfamily A Member 1

Ensembl ID : ENSACIG00000012465
Gene Symbol: CYP19A1
2 Cross references
246 Possible Orthologues:

Cytochrome P450, Family 17, Subfamily A, Polypeptide 1

Ensembl ID : ENSACIG00000019699
Gene Symbol: CYP17A1
1 Cross references
211 Possible Orthologues:

Cytochrome P450, Family 19, Subfamily A, Polypeptide 1a

Ensembl ID : ENSACIG00000000691
Gene Symbol: CYP19A1A
1 Cross references
252 Possible Orthologues:

Cytochrome P450, Family 26, Subfamily A, Polypeptide 1

Ensembl ID : ENSACIG00000002884
Gene Symbol: CYP26A1
1 Cross references
194 Possible Orthologues:

Cytochrome P450, Family 3, Subfamily A, Polypeptide 65

Ensembl ID : ENSACIG00000017550
Gene Symbol: CYP3A65
1 Cross references
569 Possible Orthologues:

Cytochrome P450, Family 3, Subfamily A, Polypeptide 65

Ensembl ID : ENSACIG00000016717
Gene Symbol: CYP3A65
1 Cross references
569 Possible Orthologues:

Cytochrome P450, Family 3, Subfamily A, Polypeptide 65

Ensembl ID : ENSACIG00000016506
Gene Symbol: CYP3A65
1 Cross references
569 Possible Orthologues:

Cytochrome P450, Family 3, Subfamily A, Polypeptide 65

Ensembl ID : ENSACIG00000015785
Gene Symbol: CYP3A65
1 Cross references
569 Possible Orthologues:

Diacylglycerol O-Acyltransferase 1a

Ensembl ID : ENSACIG00000014435
Gene Symbol: DGAT1A
1 Cross references
192 Possible Orthologues:

Diacylglycerol O-Acyltransferase 1b

Ensembl ID : ENSACIG00000013626
Gene Symbol: DGAT1B
1 Cross references
188 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).